Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 13.159
Filtrer
1.
J Nutr Sci ; 13: e34, 2024.
Article de Anglais | MEDLINE | ID: mdl-39314530

RÉSUMÉ

Coffee is one of the most popular beverages worldwide, and there is an increasing concern of the health risk of coffee consumption in pregnancy. Preeclampsia (PE) is a serious pregnancy disease that causes elevated blood pressure and proteinuria in pregnant women and growth restriction of fetuses due to poorly developed placental vasculature. The aim of our study is to investigate the possible effect of coffee intake during pregnancy in rats with potential underlying vasculature conditions. The endothelial nitric oxide synthase inhibitor N(gamma)-nitro-L-arginine methyl ester (L-NAME) at a high dose (125 mg/kg/d) was used to induce PE in pregnant rats, which were used as the positive control group. In addition, low-dose L-NAME (10 mg/kg/d) was used to simulate the compromised placental vasculature function in pregnant rats. Coffee was given together with low-dose L-NAME to the pregnant rats from gestational day 10.5-18.5. Our results show that the pregnant rats treated with low-dose L-NAME + coffee, but not low-dose L-NAME alone, developed PE symptoms such as prominent fetal growth restriction, hypertension, and proteinuria. Therefore, our findings suggest that coffee intake during pregnancy may cause an increased risk of PE in susceptible women.


Sujet(s)
Café , L-NAME , Pré-éclampsie , Protéinurie , Animaux , Grossesse , Femelle , L-NAME/pharmacologie , Rats , Retard de croissance intra-utérin , Pression sanguine , Placenta , Rat Sprague-Dawley , Antienzymes/pharmacologie , Hypertension artérielle , Nitric oxide synthase type III/métabolisme , Modèles animaux de maladie humaine
2.
Behav Pharmacol ; 35(7): 399-407, 2024 Oct 01.
Article de Anglais | MEDLINE | ID: mdl-39230435

RÉSUMÉ

The l -arginine ( l -Arg)/nitric oxide/cyclic GMP/potassium channel (K ATP ) pathway and opioid receptors are known to play critical roles in pain perception and the antinociceptive effects of various compounds. While there is evidence suggesting that the analgesic effects of rutin may involve nitric oxide modulation, the direct link between rutin and the l -Arg/nitric oxide/cyclic GMP/K ATP pathway in the context of pain modulation requires further investigation. The antinociceptive effect of rutin was studied in male NMRI mice using the formalin test. To investigate the role of the l -Arg/nitric oxide/cyclic GMP/K ATP pathway and opioid receptors, the mice were pretreated intraperitoneally with different substances. These substances included l -Arg (a precursor of nitric oxide), S-nitroso- N -acetylpenicillamine (SNAP, a nitric oxide donor), N(gamma)-nitro- l -arginine methyl ester (L-NAME, an inhibitor of nitric oxide synthase), sildenafil (an inhibitor of phosphodiesterase enzyme), glibenclamide (a K ATP channel blocker), and naloxone (an opioid receptor antagonist). All pretreatments were administered 20 min before the administration of the most effective dose of rutin. Based on our investigation, it was found that rutin exhibited a dose-dependent antinociceptive effect. The administration of SNAP enhanced the analgesic effects of rutin during both the initial and secondary phases. Moreover, L-NAME, naloxone, and glibenclamide reduced the analgesic effects of rutin in both the primary and secondary phases. In conclusion, rutin holds significant value as a flavonoid with analgesic properties, and its analgesic effect is directly mediated through the nitric oxide/cyclic GMP/K ATP channel pathway.


Sujet(s)
Analgésiques , Arginine , GMP cyclique , Canaux KATP , L-NAME , Monoxyde d'azote , Récepteurs aux opioïdes , Rutoside , Transduction du signal , Animaux , Mâle , Souris , Arginine/pharmacologie , Monoxyde d'azote/métabolisme , Rutoside/pharmacologie , Analgésiques/pharmacologie , Transduction du signal/effets des médicaments et des substances chimiques , Récepteurs aux opioïdes/métabolisme , Récepteurs aux opioïdes/effets des médicaments et des substances chimiques , Canaux KATP/métabolisme , GMP cyclique/métabolisme , L-NAME/pharmacologie , Glibenclamide/pharmacologie , Citrate de sildénafil/pharmacologie , Mesure de la douleur/effets des médicaments et des substances chimiques , Mesure de la douleur/méthodes , Naloxone/pharmacologie , Sulfones/pharmacologie , Pipérazines/pharmacologie , Purines/pharmacologie , N-Acétyl-S-nitroso-pénicillamine/pharmacologie , Douleur/traitement médicamenteux , Douleur/métabolisme , Antagonistes narcotiques/pharmacologie , Relation dose-effet des médicaments , Donneur d'oxyde nitrique/pharmacologie
3.
PLoS One ; 19(9): e0308338, 2024.
Article de Anglais | MEDLINE | ID: mdl-39240961

RÉSUMÉ

There is evidence that nitric oxide (NO) modulates the metabolism of glucose and lipid, and some antihypertensive medications have been shown to affect glucose and lipid metabolism. Peristrophe bivalvis is a medicinal plant that has been shown to have antihypertensive properties. The study investigated the effect of aqueous extract of Peristrophe bivalvis leaf (APB) on fasting blood glucose level (FBG) and lipid profile in rats pretreated with nitro-L-arginine methyl ester (L-NAME). Male Wistar rats (150-170 g, n=30) were randomly divided into two groups: control (CT, n=5) and L-NAME pretreated (n=25). CT received 5 mL/kg of distilled water [DW]) while L-NAME pretreated group received 60 mg/kg of L-NAME (L-NAME60) for eight weeks. After eight weeks, the L-NAME pretreated group was randomly subdivided into L-NAME group (LN), L-NAME recovery group (LRE), L-NAME ramipril group (LRA), and L-NAME APB group (LAPB). The groups received L-NAME60+DW, DW, L-NAME60+10 mg/kg ramipril, and L-NAME60+APB (200 mg/kg), respectively, for five weeks. Serum NO, lipid profile, cyclic guanosine monophosphate (cGMP), and insulin were measured by spectrophotometry, assay kits, and ELISA, respectively. Data were analysed using ANOVA at p < 0.05. At the eighth week, a fall in FBG and an increase in triglyceride, total cholesterol, and low-density lipoprotein cholesterol were recorded in L8 compared to CT. The same effects were also noticed in the thirteenth week in LN. However, FBG was significantly increased and lipid levels were decreased in LAPB compared to LN. A significant increase was observed in cGMP level in LAPB compared to LN. The study showed that APB corrected the hyperlipidemia and hypoglycemia caused by L-NAME, and this effect might be via the activation of cGMP.


Sujet(s)
Glycémie , Lipides , L-NAME , Extraits de plantes , Feuilles de plante , Rat Wistar , Animaux , Mâle , Extraits de plantes/pharmacologie , Glycémie/métabolisme , Glycémie/effets des médicaments et des substances chimiques , L-NAME/pharmacologie , Feuilles de plante/composition chimique , Rats , Lipides/sang , Nitric oxide synthase/antagonistes et inhibiteurs , Nitric oxide synthase/métabolisme , Monoxyde d'azote/métabolisme , Monoxyde d'azote/sang , Antienzymes/pharmacologie
4.
Cell Biochem Funct ; 42(7): e4119, 2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-39244707

RÉSUMÉ

In the present study, we investigated whether curcumin administration would interfere with the main renal features of l-NAME-induced hypertension model. For this purpose, we conducted both in vitro and in vivo experiments to evaluate renal indicators of inflammation, oxidative stress, and metalloproteinases (MMPs) expression/activity. Hypertension was induced by l-NAME (70 mg/kg/day), and Wistar rats from both control and hypertensive groups were treated with curcumin (50 or 100 mg/kg/day; gavage) or vehicle for 14 days. Blood and kidneys were collected to determine serum creatinine levels, histological alterations, oxidative stress, MMPs expression and activity, and ED1 expression. l-NAME increased blood pressure, but both doses of curcumin treatment reduced these values. l-NAME treatment increased creatinine levels, glomeruli area, Bowman's space, kidney MMP-2 activity, as well as MMP-9 and ED1 expression, and reduced the number of glomeruli. Curcumin treatment prevented the increase in creatinine levels, MMP-2 activity, and reduced MMP-2, MMP-9, ED1, and superoxide levels, as well as increased superoxide dismutase activity and partially prevented glomeruli alterations. Moreover, curcumin directly inhibited MMP-2 activity in vitro. Thus, our main findings demonstrate that curcumin reduced l-NAME-induced hypertension and renal glomerular alterations, inhibited MMP-2 and MMP-9 expression/activity, and reduced oxidative stress and inflammatory processes, which may indirectly impact hypertension-induced renal outcomes.


Sujet(s)
Curcumine , Hypertension artérielle , Matrix metalloproteinase 2 , Matrix metalloproteinase 9 , L-NAME , Rat Wistar , Animaux , Curcumine/pharmacologie , Matrix metalloproteinase 2/métabolisme , Matrix metalloproteinase 9/métabolisme , L-NAME/pharmacologie , Hypertension artérielle/induit chimiquement , Hypertension artérielle/traitement médicamenteux , Hypertension artérielle/métabolisme , Rats , Mâle , Rein/effets des médicaments et des substances chimiques , Rein/anatomopathologie , Rein/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Maladies du rein/induit chimiquement , Maladies du rein/prévention et contrôle , Maladies du rein/anatomopathologie , Maladies du rein/métabolisme , Maladies du rein/traitement médicamenteux
5.
Sci Rep ; 14(1): 19347, 2024 08 20.
Article de Anglais | MEDLINE | ID: mdl-39164321

RÉSUMÉ

The aim of this study was to investigate the possible protective effects of apelin, which is known to have antioxidant and anti-inflammatory effects, on changes in neurogenesis in newborns of pregnant rats with L-NAME-induced preeclampsia. Wistar albino female rats were divided into four experimental groups: Control, Apelin, Preeclampsia and Preeclampsia + Apelin. Blood pressure was measured on the 5th, 11th and 17th days of gestation, urine protein was analyzed from urine samples collected for 24 h on the 6th, 12th and 18th days and serum creatinine was analyzed from serum samples. Maternal kidney and placenta tissues were obtained to establish the preeclampsia model, and neonatal brain tissues including the cortex, hippocampus and cerebellum regions were obtained to investigate neurogenesis and examined by histological and immunohistochemical methods. The number of newborns, body weight and brain weight of the newborns were measured. eNOS, IL-10, nNOS and NO levels in the brain analyzed via ELISA. Mean arterial pressure, urine protein and serum creatinine increased in the preeclampsia. Newborn weight decreased in the Preeclampsia group, the values in the Preeclampsia + Apelin group were closer to the Control and Apelin groups. In the Preeclampsia group, edema and dilatation in the proximal and distal tubules of kidneys, perivillous fibrin deposition and increase in syncytial nodules of placenta were observed. VEGF immunoreactivity decreased and iNOS immunoreactivity increased in both kidney and placenta. In neonatal brain tissue examinations, cytotoxic edema accompanied by thinning of cortex, delayed migration and lower cell counts in the hippocampus, and increase in intercellular spaces and EGL thickening in the cerebellum were observed in the preeclampsia. Expression of NeuN, GFAP, MBP, IL-10, eNOS, nNOS and NO levels decreased, whereas expression of Iba-1 increased in the preeclampsia. In the Preeclampsia + Apelin group, these findings were similar to the Control and Apelin groups. Apelin administration was found to be beneficial for preventing the adverse consequences of preeclampsia, but further experimental and clinical studies are needed to better understand these effects.


Sujet(s)
Animaux nouveau-nés , Apeline , Encéphale , L-NAME , Neurogenèse , Pré-éclampsie , Rat Wistar , Femelle , Grossesse , Pré-éclampsie/induit chimiquement , Pré-éclampsie/métabolisme , Animaux , Apeline/métabolisme , Neurogenèse/effets des médicaments et des substances chimiques , Rats , Encéphale/métabolisme , Encéphale/anatomopathologie , Encéphale/effets des médicaments et des substances chimiques , L-NAME/pharmacologie , Placenta/métabolisme , Modèles animaux de maladie humaine , Nitric oxide synthase type III/métabolisme , Monoxyde d'azote/métabolisme , Interleukine-10/métabolisme , Interleukine-10/sang , Nitric oxide synthase type I/métabolisme
6.
Physiol Rep ; 12(15): e16147, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-39097984

RÉSUMÉ

The cardioprotective effect of ischemic preconditioning (IPC) and ischemic postconditioning (IPoC) in adult hearts is mediated by nitric oxide (NO). During the early developmental period, rat hearts exhibit higher resistance to ischemia-reperfusion (I/R) injury, contain higher levels of serum nitrates, and their resistance cannot be further increased by IPC or IPoC. NOS blocker (L-NAME) lowers their high resistance. Wistar rat hearts (postnatal Days 1 and 10) were perfused according to Langendorff and exposed to 40 min of global ischemia followed by reperfusion with or without IPoC. NO and reactive oxygen species donors (DEA-NONO, SIN-1) and L-NAME were administered. Tolerance to ischemia decreased between Days 1 and 10. DEA-NONO (low concentrations) significantly increased tolerance to I/R injury on both Days 1 and 10. SIN-1 increased tolerance to I/R injury on Day 10, but not on Day 1. L-NAME significantly reduced resistance to I/R injury on Day 1, but actually increased resistance to I/R injury on Day 10. Cardioprotection by IPoC on Day 10 was not affected by either NO donors or L-NAME. It can be concluded that resistance of the neonatal heart to I/R injury is NO dependent, but unlike in adult hearts, cardioprotective interventions, such as IPoC, are most likely NO independent.


Sujet(s)
Animaux nouveau-nés , Postconditionnement ischémique , Lésion de reperfusion myocardique , L-NAME , Monoxyde d'azote , Rat Wistar , Animaux , Monoxyde d'azote/métabolisme , Postconditionnement ischémique/méthodes , Lésion de reperfusion myocardique/prévention et contrôle , Lésion de reperfusion myocardique/métabolisme , Rats , L-NAME/pharmacologie , Préconditionnement ischémique myocardique/méthodes , Donneur d'oxyde nitrique/pharmacologie , Mâle , Coeur/effets des médicaments et des substances chimiques , Myocarde/métabolisme , Molsidomine/pharmacologie , Molsidomine/analogues et dérivés
7.
Life Sci ; 355: 122995, 2024 Oct 15.
Article de Anglais | MEDLINE | ID: mdl-39159720

RÉSUMÉ

AIMS: Tacrolimus is an effective immunosuppressant commonly used post-transplantation and in certain autoimmune diseases. However, its long-term administration is associated with renal fibrosis through transforming growth factor-beta/suppressor of mother against decapentaplegic (TGF-ß/Smad) signaling that could be partly attributed to endothelial dysfunction alongside decreased nitric oxide (NO) release. Our study aimed to investigate the prospective renal anti-fibrotic effect of enhanced NO production by nebivolol against tacrolimus-stimulated TGF-ß1/Smad3 signaling. MATERIALS AND METHODS: To illustrate the proposed mechanism of nebivolol, Nω-nitro-L-arginine methyl ester (L-NAME); nitric oxide synthase inhibitor; was co-administered with nebivolol. Rats were treated for 30 days as control, tacrolimus, tacrolimus/nebivolol, tacrolimus/L-NAME, and tacrolimus/nebivolol/L-NAME groups. KEY FINDINGS: Our results revealed that renal NO content was reduced in tacrolimus-treated rats, while treatment with tacrolimus/nebivolol enhanced NO content via up-regulated endothelial nitric oxide synthase (eNOS), but down-regulated inducible nitric oxide synthase (iNOS) expression. That participated in the inhibition of TGF-ß1/Smad3 signaling induced by tacrolimus, where the addition of L-NAME abolished the defensive effects of nebivolol. Subsequently, the deposition of collagen I and alpha-smooth muscle actin (α-SMA) was retarded by nebivolol, emphasized by reduced Masson's trichrome staining. In accordance, there was a strong negative correlation between eNOS and both TGF-ß1 and collagen I protein expression. The protective effects of nebivolol were further confirmed by the improvement in kidney function biomarkers and histological features. SIGNIFICANCE: It can be suggested that treatment with nebivolol along with tacrolimus could effectively suppress renal TGF-ß1/Smad3 fibrotic signaling via the enhancement of endothelial NO production, thus curbing renal fibrosis development.


Sujet(s)
Collagène de type I , Rein , Nébivolol , Nitric oxide synthase type III , Monoxyde d'azote , Transduction du signal , Protéine Smad-3 , Tacrolimus , Facteur de croissance transformant bêta-1 , Animaux , Nébivolol/pharmacologie , Protéine Smad-3/métabolisme , Monoxyde d'azote/métabolisme , Tacrolimus/pharmacologie , Facteur de croissance transformant bêta-1/métabolisme , Rats , Nitric oxide synthase type III/métabolisme , Mâle , Transduction du signal/effets des médicaments et des substances chimiques , Rein/métabolisme , Rein/effets des médicaments et des substances chimiques , Rein/anatomopathologie , Collagène de type I/métabolisme , Immunosuppresseurs/pharmacologie , Fibrose , L-NAME/pharmacologie , Rat Wistar , Rat Sprague-Dawley
8.
Int J Mol Sci ; 25(14)2024 Jul 13.
Article de Anglais | MEDLINE | ID: mdl-39062939

RÉSUMÉ

Recently, we compared an interplay of the adenosine system and nitric oxide (NO) in the regulation of renal function between male normoglycaemic (NG) and streptozotocin-induced diabetic rats (DM). Considering the between-sex functional differences, e.g., in the NO status, we present similar studies performed in female rats. We examined if the theophylline effects (non-selective adenosine antagonist) in NG and DM females with or without active NO synthases differed from the earlier findings. In anaesthetised female Sprague Dawley rats, both NG and DM, untreated or after NO synthesis blockade with L-NAME, theophylline effects, on blood pressure, renal hemodynamics and excretion, and renal tissue NO were investigated. Renal artery blood flow (Transonic probe), cortical, outer-, and inner-medullary flows (laser-Doppler technique), and renal tissue NO signal (selective electrode) were measured. In contrast to males, in female NG and DM rats, theophylline induced renal vasodilation. In NO-deficient females, theophylline induced comparable renal vasodilatation, confirming the vasoconstrictor influence of the renal adenosine. In NG and DM females with intact NO synthesis, adenosine inhibition diminished kidney tissue NO, contrasting with an increase reported in males. Lowered baseline renal excretion in DM females suggested stimulation of renal tubular reabsorption due to the prevalence of antinatriuretic over natriuretic tubular action of adenosine receptors. An opposite inter-receptor balance pattern emerged previously from male studies. The study exposed between-sex functional differences in the interrelation of adenosine and NO in rats with normoglycaemia and streptozotocin diabetes. The findings also suggest that in diabetes mellitus, the abundance of individual receptor types can distinctly differ between females and males.


Sujet(s)
Adénosine , Diabète expérimental , Hémodynamique , Rein , Monoxyde d'azote , Rat Sprague-Dawley , Théophylline , Animaux , Diabète expérimental/métabolisme , Diabète expérimental/physiopathologie , Femelle , Monoxyde d'azote/métabolisme , Mâle , Adénosine/métabolisme , Rats , Rein/métabolisme , Théophylline/pharmacologie , Streptozocine , Caractères sexuels , L-NAME/pharmacologie , Pression sanguine/effets des médicaments et des substances chimiques
9.
Clin Sci (Lond) ; 138(14): 901-920, 2024 Jul 17.
Article de Anglais | MEDLINE | ID: mdl-38949825

RÉSUMÉ

We reported that salt-sensitive hypertension (SSHTN) is associated with increased pro-inflammatory immune cells, inflammation, and inflammation-associated lymphangiogenesis in the kidneys and gonads of male and female mice. However, it is unknown whether these adverse end organ effects result from increased blood pressure (BP), elevated levels of salt, or both. We hypothesized that pharmaceutically lowering BP would not fully alleviate the renal and gonadal immune cell accumulation, inflammation, and lymphangiogenesis associated with SSHTN. SSHTN was induced in male and female C57BL6/J mice by administering nitro-L-arginine methyl ester hydrochloride (L-NAME; 0.5 mg/ml) in their drinking water for 2 weeks, followed by a 2-week washout period. Subsequently, the mice received a 3-week 4% high salt diet (SSHTN). The treatment group underwent the same SSHTN induction protocol but received hydralazine (HYD; 250 mg/L) in their drinking water during the diet phase (SSHTN+HYD). Control mice received tap water and a standard diet for 7 weeks. In addition to decreasing systolic BP, HYD treatment generally decreased pro-inflammatory immune cells and inflammation in the kidneys and gonads of SSHTN mice. Furthermore, the decrease in BP partially alleviated elevated renal and gonadal lymphatics and improved renal and gonadal function in mice with SSHTN. These data demonstrate that high systemic pressure and salt differentially act on end organ immune cells, contributing to the broader understanding of how BP and salt intake collectively shape immune responses and highlight implications for targeted therapeutic interventions.


Sujet(s)
Pression sanguine , Hypertension artérielle , Inflammation , Rein , Souris de lignée C57BL , Chlorure de sodium alimentaire , Animaux , Hypertension artérielle/immunologie , Hypertension artérielle/physiopathologie , Hypertension artérielle/traitement médicamenteux , Hypertension artérielle/induit chimiquement , Mâle , Femelle , Pression sanguine/effets des médicaments et des substances chimiques , Chlorure de sodium alimentaire/effets indésirables , Rein/immunologie , Rein/effets des médicaments et des substances chimiques , Inflammation/immunologie , Lymphangiogenèse/effets des médicaments et des substances chimiques , Antihypertenseurs/pharmacologie , Souris , Hydralazine/pharmacologie , L-NAME/pharmacologie , Modèles animaux de maladie humaine , Gonades/effets des médicaments et des substances chimiques
10.
Int J Mol Sci ; 25(13)2024 Jun 30.
Article de Anglais | MEDLINE | ID: mdl-39000349

RÉSUMÉ

Lipid emulsions are used as adjuvant drugs to alleviate intractable cardiovascular collapse induced by drug toxicity. We aimed to examine the effect of lipid emulsions on labetalol-induced vasodilation and the underlying mechanism in the isolated rat aorta. We studied the effects of endothelial denudation, NW-nitro-l-arginine methyl ester (l-NAME), calmidazolium, methylene blue, 1H-[1,2,4]oxadiazolo[4,3-a] quinoxalin-1-one (ODQ), and lipid emulsions on labetalol-induced vasodilation. We also evaluated the effects of lipid emulsions on cyclic guanosine monophosphate (cGMP) formation, endothelial nitric oxide synthase (eNOS) phosphorylation, and endothelial calcium levels induced by labetalol. Labetalol-induced vasodilation was higher in endothelium-intact aortas than that in endothelium-denuded aortas. l-NAME, calmidazolium, methylene blue, and ODQ inhibited labetalol-induced vasodilation in endothelium-intact aortas. Lipid emulsions inhibited labetalol-induced vasodilation in endothelium-intact and endothelium-denuded aortas. l-NAME, ODQ, and lipid emulsions inhibited labetalol-induced cGMP formation in endothelium-intact aortas. Lipid emulsions reversed the stimulatory and inhibitory eNOS (Ser1177 and Thr495) phosphorylation induced by labetalol in human umbilical vein endothelial cells and inhibited the labetalol-induced endothelial calcium increase. Moreover, it decreased labetalol concentration. These results suggest that lipid emulsions inhibit vasodilation induced by toxic doses of labetalol, which is mediated by the inhibition of endothelial nitric oxide release and reduction of labetalol concentration.


Sujet(s)
Aorte , GMP cyclique , Émulsions , Labétalol , Nitric oxide synthase type III , Vasodilatation , Animaux , Vasodilatation/effets des médicaments et des substances chimiques , Rats , Aorte/effets des médicaments et des substances chimiques , Aorte/métabolisme , Labétalol/pharmacologie , Mâle , Nitric oxide synthase type III/métabolisme , GMP cyclique/métabolisme , Endothélium vasculaire/effets des médicaments et des substances chimiques , Endothélium vasculaire/métabolisme , Rat Sprague-Dawley , Humains , Lipides , Phosphorylation/effets des médicaments et des substances chimiques , Calcium/métabolisme , L-NAME/pharmacologie , Cellules endothéliales de la veine ombilicale humaine/effets des médicaments et des substances chimiques , Cellules endothéliales de la veine ombilicale humaine/métabolisme
11.
Cell Biochem Funct ; 42(5): e4095, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-39004810

RÉSUMÉ

This study aimed to investigate the effects of the n-hexane fraction of the ethanolic seed extract of PG (NFESEPG) on hypertension induced by Nω-nitro-L-arginine methyl ester (L-NAME) in rats. Specifically, the study examined the impact of NFESEPG on blood pressure, oxidative stress markers, NO concentration, angiotensin-converting enzyme (ACE) and arginase activities, and cardiac biomarkers in hypertensive rats. The study involved collecting, identifying, and processing the PG plant to obtain the ethanolic seed extract. The extract was then partitioned with solvents to isolate the n-hexane fraction. Hypertension was induced in rats by oral administration of L-NAME for 10 days, while concurrent treatment with NFESEPG at two doses (200 and 400 mg/kg/day) was administered orally. Blood pressure was measured using a noninvasive tail-cuff method, and various biochemical parameters were assessed. Treatment with both doses of NFESEPG significantly reduced systolic and diastolic blood pressure in L-NAME-induced hypertensive rats. Additionally, NFESEPG administration increased NO concentration and decreased ACE and arginase activities, malondialdehyde (MDA) levels, and cardiac biomarkers in hypertensive rats. The findings indicate that NFESEPG effectively lowered blood pressure in hypertensive rats induced by L-NAME, potentially through mechanisms involving the modulation of oxidative stress, NO bioavailability, and cardiac biomarkers. These results suggest the therapeutic potential of NFESEPG in managing hypertension and related cardiovascular complications.


Sujet(s)
Hexanes , Hypertension artérielle , L-NAME , Piper , Extraits de plantes , Graines , Animaux , Extraits de plantes/pharmacologie , Extraits de plantes/composition chimique , Hypertension artérielle/traitement médicamenteux , Hypertension artérielle/induit chimiquement , Hypertension artérielle/métabolisme , Rats , L-NAME/pharmacologie , Mâle , Graines/composition chimique , Hexanes/composition chimique , Piper/composition chimique , Pression sanguine/effets des médicaments et des substances chimiques , Stress oxydatif/effets des médicaments et des substances chimiques , Rat Wistar , Monoxyde d'azote/métabolisme , Arginase/métabolisme , Peptidyl-Dipeptidase A/métabolisme
12.
Food Res Int ; 191: 114717, 2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-39059914

RÉSUMÉ

To reveal the interaction of oxidative stress and protein S-nitrosylation on mitochondrial pathway apoptosis and tenderness development in postmortem yak meat. Herein, we selected yak longissimus dorsi muscle as the research object and treated hydrogen peroxide (H2O2) with S-nitrosoglutathione agent (GSNO) as well as Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME) in mixed injections with 0.9 % saline as a control group, followed by incubation at 4 °C for 12, 24, 72, 120 and 168 h. Results showed that this interaction significantly increased mitochondrial ROS and NO content (P < 0.05) while weakening the antioxidant capacity of GSH and TRX redox response systems or accelerating the Ca2+ release process, leading to mitochondrial functional impairment and increased apoptosis rate. Notably, the H2O2 + L-NAME group showed more pronounced apoptosis. Hence, we suggest that the interaction between oxidative stress and protein S-nitrosylation could positively regulate yak meat tenderization.


Sujet(s)
Apoptose , Peroxyde d'hydrogène , Stress oxydatif , Animaux , Apoptose/effets des médicaments et des substances chimiques , Stress oxydatif/effets des médicaments et des substances chimiques , Bovins , Peroxyde d'hydrogène/métabolisme , Mitochondries/métabolisme , Mitochondries/effets des médicaments et des substances chimiques , L-NAME/pharmacologie , Muscles squelettiques/métabolisme , Muscles squelettiques/effets des médicaments et des substances chimiques , Monoxyde d'azote/métabolisme , Viande/analyse , Modifications postmortem , Espèces réactives de l'oxygène/métabolisme , S-Nitroso-glutathion/pharmacologie , S-Nitroso-glutathion/métabolisme , Antioxydants/métabolisme , Antioxydants/pharmacologie
13.
Am J Physiol Heart Circ Physiol ; 327(4): H793-H803, 2024 Oct 01.
Article de Anglais | MEDLINE | ID: mdl-39058435

RÉSUMÉ

Women with a history of gestational diabetes mellitus (GDM) have a significantly greater lifetime risk of developing cardiovascular disease and type 2 diabetes compared with women who had an uncomplicated pregnancy (HC). Microvascular endothelial dysfunction, mediated via reduced nitric oxide (NO)-dependent dilation secondary to increases in oxidative stress, persists after pregnancy complicated by GDM. We examined whether this microvascular dysfunction reduces insulin-mediated vascular responses in women with a history of GDM. We assessed in vivo microvascular endothelium-dependent vasodilator function by measuring cutaneous vascular conductance responses to graded infusions of acetylcholine (10-10-10-1 M) and insulin (10-8-10-4 M) in control sites and sites treated with 15 mM l-NAME [NG-nitro-l-arginine methyl ester; NO-synthase (NOS) inhibitor] or 5 mM l-ascorbate. We also measured protein expression of total endothelial NOS (eNOS), insulin-mediated eNOS phosphorylation, and endothelial nitrotyrosine in isolated endothelial cells from GDM and HC. Women with a history of GDM had reduced acetylcholine (P < 0.001)- and insulin (P < 0.001)-mediated dilation, and the NO-dependent responses to both acetylcholine (P = 0.006) and insulin (P = 0.006) were reduced in GDM compared with HC. Insulin stimulation increased phosphorylated eNOS content in HC (P = 0.009) but had no effect in GDM (P = 0.306). Ascorbate treatment increased acetylcholine (P < 0.001)- and insulin (P < 0.001)-mediated dilation in GDM, and endothelial cell nitrotyrosine expression was higher in GDM compared with HC (P = 0.014). Women with a history of GDM have attenuated microvascular vasodilation responses to insulin, and this attenuation is mediated, in part, by reduced NO-dependent mechanisms. Our findings further implicate increased endothelial oxidative stress in this microvascular insulin resistance.NEW & NOTEWORTHY Women who have gestational diabetes during pregnancy are at a greater risk for cardiovascular disease and type 2 diabetes in the decade following pregnancy. The mechanisms mediating this increased risk are unclear. Herein, we demonstrate that insulin-dependent microvascular responses are reduced in women who had gestational diabetes, despite the remission of glucose intolerance. This reduced microvascular sensitivity to insulin may contribute to increased cardiovascular disease and type 2 diabetes risk in these women.


Sujet(s)
Diabète gestationnel , Insuline , Microvaisseaux , Nitric oxide synthase type III , Monoxyde d'azote , Vasodilatation , Femelle , Diabète gestationnel/physiopathologie , Diabète gestationnel/métabolisme , Humains , Grossesse , Vasodilatation/effets des médicaments et des substances chimiques , Insuline/pharmacologie , Adulte , Nitric oxide synthase type III/métabolisme , Monoxyde d'azote/métabolisme , Microvaisseaux/métabolisme , Microvaisseaux/effets des médicaments et des substances chimiques , Microvaisseaux/physiopathologie , Acétylcholine/pharmacologie , Vasodilatateurs/pharmacologie , Phosphorylation , Stress oxydatif/effets des médicaments et des substances chimiques , Endothélium vasculaire/métabolisme , Endothélium vasculaire/physiopathologie , Endothélium vasculaire/effets des médicaments et des substances chimiques , Tyrosine/analogues et dérivés , Tyrosine/métabolisme , Études cas-témoins , L-NAME/pharmacologie , Peau/vascularisation
14.
Arch Biochem Biophys ; 758: 110059, 2024 08.
Article de Anglais | MEDLINE | ID: mdl-38936683

RÉSUMÉ

BACKGROUND: It has been previously demonstrated that the maintenance of ischemic acidic pH or the delay of intracellular pH recovery at the onset of reperfusion decreases ischemic-induced cardiomyocyte death. OBJECTIVE: To examine the role played by nitric oxide synthase (NOS)/NO-dependent pathways in the effects of acidic reperfusion in a regional ischemia model. METHODS: Isolated rat hearts perfused by Langendorff technique were submitted to 40 min of left coronary artery occlusion followed by 60 min of reperfusion (IC). A group of hearts received an acid solution (pH = 6.4) during the first 2 min of reperfusion (AR) in absence or in presence of l-NAME (NOS inhibitor). Infarct size (IS) and myocardial function were determined. In cardiac homogenates, the expression of P-Akt, P-endothelial and inducible isoforms of NOS (P-eNOS and iNOS) and the level of 3-nitrotyrosine were measured. In isolated cardiomyocytes, the intracellular NO production was assessed by confocal microscopy, under control and acidic conditions. Mitochondrial swelling after Ca2+ addition and mitochondrial membrane potential (Δψ) were also determined under control and acidosis. RESULTS: AR decreased IS, improved postischemic myocardial function recovery, increased P-Akt and P-eNOS, and decreased iNOS and 3-nitrotyrosine. NO production increased while mitochondrial swelling and Δψ decreased in acidic conditions. l-NAME prevented the beneficial effects of AR. CONCLUSIONS: Our data strongly supports that a brief acidic reperfusion protects the myocardium against the ischemia-reperfusion injury through eNOS/NO-dependent pathways.


Sujet(s)
Monoxyde d'azote , Animaux , Concentration en ions d'hydrogène , Monoxyde d'azote/métabolisme , Mâle , Rats , Rat Wistar , Nitric oxide synthase type III/métabolisme , Myocytes cardiaques/métabolisme , Myocytes cardiaques/effets des médicaments et des substances chimiques , Myocytes cardiaques/anatomopathologie , Lésion de reperfusion myocardique/métabolisme , Lésion de reperfusion myocardique/anatomopathologie , Lésion de reperfusion myocardique/prévention et contrôle , Lésion de reperfusion myocardique/traitement médicamenteux , L-NAME/pharmacologie , Protéines proto-oncogènes c-akt/métabolisme , Nitric oxide synthase type II/métabolisme , Potentiel de membrane mitochondriale/effets des médicaments et des substances chimiques , Ischémie myocardique/métabolisme , Ischémie myocardique/anatomopathologie , Nitric oxide synthase/métabolisme
15.
Am J Physiol Heart Circ Physiol ; 327(2): H364-H369, 2024 08 01.
Article de Anglais | MEDLINE | ID: mdl-38847757

RÉSUMÉ

The transcriptional regulator nuclear factor-κB (NF-κB) is a mediator of endothelial dysfunction. Inhibiting NF-κB with salsalate is used to investigate inflammatory mechanisms contributing to accelerated cardiovascular disease risk. However, in the absence of disease, inhibition of NF-κB can impact redox mechanisms, resulting in paradoxically decreased endothelial function. This study aimed to measure microvascular endothelial function during inhibition of the transcriptional regulator NF-κB in reproductive-aged healthy women. In a randomized, single-blind, crossover, placebo-controlled design, nine healthy women were randomly assigned oral salsalate (1,500 mg, twice daily) or placebo treatments for 5 days. Subjects underwent graded perfusion with the endothelium-dependent agonist acetylcholine (ACh, 10-10 to 10-1 M, 33°C) alone and in combination with 15 mM NG-nitro-l-arginine methyl ester [l-NAME; nonselective nitric oxide (NO) synthase inhibitor] through intradermal microdialysis. Laser-Doppler flux was measured over each microdialysis site, and cutaneous vascular conductance (CVC) was calculated as flux divided by mean arterial pressure and normalized to site-specific maximum (CVC%max; 28 mM sodium nitroprusside + 43°C). The l-NAME sensitive component was calculated as the difference between the areas under the dose-response curves. During the placebo and salsalate treatments, the l-NAME sites were reduced compared with the control sites (both P < 0.0001). Across treatments, there was a significant difference between the control and l-NAME sites, where both sites shifted upward following salsalate treatment (both P < 0.0001), whereas the l-NAME-sensitive component was not different (P = 0.94). These data demonstrate that inhibition of the transcriptional regulator NF-κB improves cutaneous microvascular function in reproductive-aged healthy women through non-NO-dependent mechanisms.NEW & NOTEWORTHY The transcription factor nuclear factor-κB (NF-κB) regulates multiple aspects of innate and adaptive immunity by encoding for genes that participate in inflammation and impact endothelial function following NF-κB inhibition with salsalate treatment. Our results show that cutaneous microvascular function is increased through non-nitric oxide (NO)-dependent mechanisms following salsalate treatment in reproductive-aged healthy women.


Sujet(s)
Études croisées , Microcirculation , Facteur de transcription NF-kappa B , Monoxyde d'azote , Peau , Humains , Femelle , Adulte , Peau/vascularisation , Peau/effets des médicaments et des substances chimiques , Peau/métabolisme , Facteur de transcription NF-kappa B/métabolisme , Méthode en simple aveugle , Microcirculation/effets des médicaments et des substances chimiques , Monoxyde d'azote/métabolisme , L-NAME/pharmacologie , Vasodilatation/effets des médicaments et des substances chimiques , Jeune adulte , Acétylcholine/pharmacologie , Volontaires sains , Vasodilatateurs/pharmacologie , Antienzymes/pharmacologie , Salicylates/pharmacologie , Microvaisseaux/effets des médicaments et des substances chimiques , Microvaisseaux/métabolisme , Endothélium vasculaire/effets des médicaments et des substances chimiques , Endothélium vasculaire/métabolisme , Débit sanguin régional/effets des médicaments et des substances chimiques
16.
Cell Tissue Res ; 397(2): 111-124, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38829397

RÉSUMÉ

Nitric oxide (NO) is a gaseous molecule that regulates various reproductive functions. It is a well-recognized regulator of GnRH-FSH/LH-sex steroid secretion in vertebrates including fish. Kisspeptin is a recently discovered neuropeptide which also regulates GnRH secretion. Nitrergic and kisspeptin neurons are reported in close physical contact in the mammalian brain suggesting their interactive role in the release of GnRH. The existence of kisspeptin and NOS is also demonstrated in vertebrate gonads, but information on their reciprocal relation in gonads, if any, is obscure. Therefore, attempts were made to evaluate the functional reciprocal relation between nitric oxide and kisspeptin in the catfish gonads, if any, by administering the nitric oxide synthase (NOS) inhibitor, L-NAME {N(G)-nitro-L-arginine methyl ester}, which reduces NO production, and kisspeptin agonist (KP-10) and assessing their impacts on the expressions of kisspeptin1, different NOS isoforms, NO and steroid production in the gonadal tissue. The results revealed that L-NAME suppressed the expression of kiss1 in gonads of the catfish establishing the role of NO in kisspeptin expression. However, KP-10 increased the expression of all the isoforms of NOSs (iNOS, eNOS, nNOS) and concurrently NO and steroids in the ovary and testis. In vitro studies also indicate that kisspeptin stimulates the production of NO and estradiol and testosterone levels in the gonadal explants and medium. Thus, in vivo results clearly suggest a reciprocal interaction between kisspeptin and NO to regulate the gonadal activity of the catfish. The in vitro findings further substantiate our contention regarding the interactive role of kisspeptin and NO in gonadal steroidogenesis.


Sujet(s)
Poissons-chats , Gamétogenèse , Kisspeptines , L-NAME , Monoxyde d'azote , Animaux , Monoxyde d'azote/métabolisme , Poissons-chats/métabolisme , Kisspeptines/métabolisme , Mâle , L-NAME/pharmacologie , Femelle , Gamétogenèse/effets des médicaments et des substances chimiques , Stéroïdes/biosynthèse , Nitric oxide synthase/métabolisme , Testicule/métabolisme , Testicule/effets des médicaments et des substances chimiques , Gonades/métabolisme , Gonades/effets des médicaments et des substances chimiques , Ovaire/métabolisme
17.
J Vasc Res ; 61(4): 166-178, 2024.
Article de Anglais | MEDLINE | ID: mdl-38880090

RÉSUMÉ

INTRODUCTION: Heart failure with preserved ejection fraction (HFpEF) is a common syndrome with high morbidity and mortality but without available evidence-based therapies. It is essential to investigate changes in gene expression profiles in preclinical HFpEF animal models, with the aim of searching for novel therapeutic targets. METHODS: Wild-type male C57BL/6J mice were administrated with a combination of high-fat diet (HFD) and inhibition of constitutive nitric oxide synthase using N-nitro-l-arginine methyl ester (l-NAME) for 5 and 7 weeks. RNA sequencing was conducted to detect gene expression profiles, and bioinformatic analysis was performed to identify the core genes, pathways, and biological processes involved. RESULTS: A total of 1,347 genes were differentially expressed in the heart at week 5 and 7 post-intervention. Gene Ontology enrichment analysis indicated that these greatly changed genes were involved mainly in cell adhesion, neutrophil chemotaxis, cell communication, and other functions. Using hierarchical cluster analysis, these differentially expressed genes were classified into 16 profiles. Of these, three significant profiles were ultimately identified. Gene co-expression network analysis suggested troponin T type 1 (Tnnt1) directly regulated 31 neighboring genes and was considered to be at the core of the associated gene network. CONCLUSION: The combined application of RNA sequencing, hierarchical cluster analysis, and gene network analysis identified Tnnt1 as the most important gene in the development of HFpEF.


Sujet(s)
Modèles animaux de maladie humaine , Analyse de profil d'expression de gènes , Réseaux de régulation génique , Défaillance cardiaque , Souris de lignée C57BL , Débit systolique , Transcriptome , Fonction ventriculaire gauche , Animaux , Mâle , Défaillance cardiaque/génétique , Défaillance cardiaque/physiopathologie , Défaillance cardiaque/métabolisme , RNA-Seq , Transduction du signal , Alimentation riche en graisse , Régulation de l'expression des gènes , L-NAME/pharmacologie , Troponine T/génétique , Troponine T/métabolisme , Myocarde/métabolisme , Myocarde/anatomopathologie , Phénotype , Souris
18.
Am J Hypertens ; 37(9): 717-725, 2024 Aug 14.
Article de Anglais | MEDLINE | ID: mdl-38780971

RÉSUMÉ

BACKGROUND: High salt (HS) intake induces an augmented hypertensive response to nitric oxide (NO) inhibition, though it causes minimal changes in blood pressure (BP) in NO intact condition. The cause of such augmentation is not known. HS induces tumor necrosis factor-alpha (TNFα) production that causes natriuresis via activation of its receptor type 1 (TNFR1). We hypothesized that NO deficiency reduces renal TNFR1 activity, leading to enhanced sodium retention and hypertension. METHODS: We examined the changes in renal TNFR1 protein expression (Immunohistochemistry analyses) after HS (4% NaCl) intake in wild-type mice (WT, C57BL6) treated with a NO synthase (NOS) inhibitor, nitro-l-arginine methyl ester (L-NAME; 0.05 mg/min/g; osmotic mini-pump), as well as in endothelial NOS knockout mice (eNOSKO) and compared the responses in WT mice with normal salt (NS; 0.3% NaCl) intake. BP was measured with tail-cuff plethysmography and 24-hour urine collections were made using metabolic cages. RESULTS: HS alone did not alter mean BP in untreated mice (76 ±â€…3 to 77 ±â€…1 mm Hg) but induced an augmented response in L-NAME treated (106 ±â€…1 vs. 97 ±â€…2 mm Hg) and in eNOSKO (107 ±â€…2 vs. 89 ±â€…3 mm Hg) mice. The percentage area of TNFR1 expression in renal tissue was higher in WT + HS (4.1 + 0.5%) than in WT + NS mice (2.7 ±â€…0.6%). However, TNFR1 expression was significantly lower in L-NAME treated WT + NS (0.9 ±â€…0.1%) and in eNOSKO + NS (1.4 ±â€…0.2%) than in both WT + NS and WT + HS mice. CONCLUSIONS: These data indicate that TNFR1 activity is downregulated in NO deficient conditions, which facilitates salt retention leading to augmented hypertension during HS intake.


Sujet(s)
Hypertension artérielle , Rein , Souris de lignée C57BL , Souris knockout , L-NAME , Monoxyde d'azote , Récepteur au facteur de nécrose tumorale de type I , Chlorure de sodium alimentaire , Animaux , Récepteur au facteur de nécrose tumorale de type I/métabolisme , Récepteur au facteur de nécrose tumorale de type I/génétique , Hypertension artérielle/métabolisme , Hypertension artérielle/physiopathologie , Monoxyde d'azote/métabolisme , Souris , Rein/métabolisme , Rein/effets des médicaments et des substances chimiques , Rein/physiopathologie , L-NAME/pharmacologie , Mâle , Pression sanguine/effets des médicaments et des substances chimiques , Nitric oxide synthase type III/métabolisme , Facteur de nécrose tumorale alpha/métabolisme
19.
Biomed Pharmacother ; 175: 116683, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38705130

RÉSUMÉ

OBJECTIVE: Blockade of activin 2 receptor (ACVR2) signaling has been shown to improve insulin sensitivity and aid in weight loss. Inhibition of ACVR2 signaling restores cardiac function in multiple heart failure models. However, its potential in the treatment of obesity-related cardiometabolic disease remains unknown. Here, we investigated targeting ACVR2 signaling in cardiometabolic disease manifested with metabolic dysfunction-associated steatotic liver disease (MASLD). METHODS: Mice were fed a high-fat, high-sugar diet combined with the administration of nitric oxide synthase inhibitor L-NAME in drinking water, which causes hypertensive stress. For the last eight weeks, the mice were treated with the soluble ACVR2B decoy receptor (sACVR2B-Fc). RESULTS: sACVR2B-Fc protected against the development of comorbidities associated with cardiometabolic disease. This was most pronounced in the liver where ACVR2 blockade attenuated the development of MASLD including cessation of pro-fibrotic activation. It also significantly reduced total plasma cholesterol levels, impeded brown adipose tissue whitening, and improved cardiac diastolic function. In vitro, ACVR2 ligands activin A, activin B and GDF11 induced profibrotic signaling and the proliferation of human cardiac fibroblasts. CONCLUSIONS: Blockade of ACVR2B exerts broad beneficial effects for therapy of cardiometabolic disease. By reducing obesity, ameliorating cardiovascular deterioration and restraining MASLD, blockade of ACVR2B signaling proves a potential target in MASLD and its comorbidities.


Sujet(s)
Récepteur activine, type 2 , Souris de lignée C57BL , L-NAME , Transduction du signal , Animaux , Transduction du signal/effets des médicaments et des substances chimiques , L-NAME/pharmacologie , Mâle , Souris , Récepteur activine, type 2/métabolisme , Humains , Régime occidental/effets indésirables , Stéatose hépatique/traitement médicamenteux , Stéatose hépatique/métabolisme , Maladies métaboliques/traitement médicamenteux , Maladies métaboliques/métabolisme , Alimentation riche en graisse/effets indésirables , Modèles animaux de maladie humaine , Maladies cardiovasculaires/traitement médicamenteux , Maladies cardiovasculaires/prévention et contrôle , Maladies cardiovasculaires/métabolisme , Foie/métabolisme , Foie/effets des médicaments et des substances chimiques , Foie/anatomopathologie
20.
Free Radic Biol Med ; 221: 89-97, 2024 Aug 20.
Article de Anglais | MEDLINE | ID: mdl-38735541

RÉSUMÉ

The complex interplay between hydrogen peroxide (H2O2) and nitric oxide (NO) in endothelial cells presents challenges due to technical limitations in simultaneous measurement, hindering the elucidation of their direct relationship. Previous studies have yielded conflicting findings regarding the impact of H2O2 on NO production. To address this problem, we employed genetically encoded biosensors, HyPer7 for H2O2 and geNOps for NO, allowing simultaneous imaging in single endothelial cells. Optimization strategies were implemented to enhance biosensor performance, including camera binning, temperature regulation, and environmental adjustments to mimic physiological normoxia. Our results demonstrate that under ambient oxygen conditions, H2O2 exhibited no significant influence on NO production. Subsequent exploration under physiological normoxia (5 kPa O2) revealed distinct oxidative stress levels characterized by reduced basal HyPer7 signals, enhanced H2O2 scavenging kinetics, and altered responses to pharmacological treatment. Investigation of the relationship between H2O2 and NO under varying oxygen conditions revealed a lack of NO response to H2O2 under hyperoxia (18 kPa O2) but a modest NO response under physiological normoxia (5 kPa O2). Importantly, the NO response was attenuated by l-NAME, suggesting activation of eNOS by endogenous H2O2 generation upon auranofin treatment. Our study highlights the intricate interplay between H2O2 and NO within the endothelial EA.hy926 cell line, emphasizing the necessity for additional research within physiological contexts due to differential response observed under physiological normoxia (5 kPa O2). This further investigation is essential for a comprehensive understanding of the H2O2 and NO signaling considering the physiological effects of ambient O2 levels involved.


Sujet(s)
Techniques de biocapteur , Cellules endothéliales , Peroxyde d'hydrogène , Nitric oxide synthase type III , Monoxyde d'azote , Stress oxydatif , Oxygène , Peroxyde d'hydrogène/métabolisme , Monoxyde d'azote/métabolisme , Humains , Oxygène/métabolisme , Cellules endothéliales/métabolisme , Cellules endothéliales/effets des médicaments et des substances chimiques , Nitric oxide synthase type III/métabolisme , Nitric oxide synthase type III/génétique , Techniques de biocapteur/méthodes , L-NAME/pharmacologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE